Literature DB >> 26984877

A retrospective observational study on the treatment outcomes of 26 patients with spinal cord astrocytoma including two cases of malignant transformation.

Seong Jun Ryu1, Jong Yul Kim1, Kyung Hyun Kim1, Jeong Yoon Park1, Sung Uk Kuh1, Dong Kyu Chin1, Keun Su Kim1, Yong Eun Cho2, Se Hoon Kim3.   

Abstract

PURPOSE: To determine the biologic behavior and prognostic factors of spinal cord astrocytoma, we reviewed surgical and clinical outcomes. Due to the rarity of spinal cord astrocytoma, there is a lack of research regarding this type of tumor and malignant transformation.
METHODS: We retrospectively reviewed the data from all patients on whom we performed spinal cord tumor removal between 1983 and 2014. Twenty-six patients were pathologically confirmed to have spinal cord astrocytoma or glioblastoma. Surgical extent and disease progression were confirmed by the surgeon based on operative findings, postoperative MRI, and outpatient department (OPD) follow-up.
RESULTS: Pain or neurological deficit was the chief complaint for all patients. With MRI studies, there is a tendency for high-grade astrocytomas to show as enhanced and heterogeneous images. Two of the low-grade astrocytomas showed malignant transformation over the course of 4 and 11 months, respectively. The overall survival (OS) for low-grade astrocytoma was 28-480 months (mean 156.38 months); the OS for high-grade astrocytoma was 1-36 months (mean 12.00 months).
CONCLUSIONS: Two of 12 low-grade cases showed malignant transformations at 4 and 11 months, respectively, based on pathological confirmation. With spinal cord astrocytomas, enhanced MRI results appeared similar to those of a malignant lesion. We suggest close observation and image correlation of low-grade astrocytomas, even when pathologically confirmed as low-grade. In this review, we found that histologic grade is the most important prognostic factor, although it is not always concordant with biologic behaviors.

Entities:  

Keywords:  Astrocytoma; Malignant glioma; Radiotherapy; Spinal cord neoplasm; Survival

Mesh:

Year:  2016        PMID: 26984877     DOI: 10.1007/s00586-016-4475-7

Source DB:  PubMed          Journal:  Eur Spine J        ISSN: 0940-6719            Impact factor:   3.134


  32 in total

1.  Prognostic factors in intramedullary astrocytomas.

Authors:  G Innocenzi; M Salvati; L Cervoni; R Delfini; G Cantore
Journal:  Clin Neurol Neurosurg       Date:  1997-02       Impact factor: 1.876

2.  High-grade pediatric spinal cord tumors.

Authors:  T E Merchant; D Nguyen; S J Thompson; D A Reardon; L E Kun; R A Sanford
Journal:  Pediatr Neurosurg       Date:  1999-01       Impact factor: 1.162

3.  Spinal cord astrocytomas: a modern 20-year experience at a single institution.

Authors:  Ranjith Babu; Isaac O Karikari; Timothy R Owens; Carlos A Bagley
Journal:  Spine (Phila Pa 1976)       Date:  2014-04-01       Impact factor: 3.468

Review 4.  Spinal cord pilocytic astrocytoma with leptomeningeal dissemination to the brain. Case report and review of the literature.

Authors:  Taylor J Abel; Abhineet Chowdhary; Mahesh Thapa; Joe C Rutledge; J Russell Geyer; Jeffrey Ojemann; Anthony M Avellino
Journal:  J Neurosurg       Date:  2006-12       Impact factor: 5.115

5.  Intramedullary spinal cord astrocytoma in adults: postoperative outcome.

Authors:  M S Kim; C K Chung; G Choe; I H Kim; H J Kim
Journal:  J Neurooncol       Date:  2001-03       Impact factor: 4.130

6.  Spinal cord malignant astrocytomas. Clinicopathologic features in 36 cases.

Authors:  Mariarita Santi; Hernando Mena; Kondi Wong; Kelly Koeller; Cara Olsen; Elisabeth J Rushing
Journal:  Cancer       Date:  2003-08-01       Impact factor: 6.860

7.  Primary spinal cord tumors treated with surgery and postoperative irradiation.

Authors:  D M Garcia
Journal:  Int J Radiat Oncol Biol Phys       Date:  1985-11       Impact factor: 7.038

8.  Extent of surgical resection of malignant astrocytomas of the spinal cord: outcome analysis of 35 patients.

Authors:  Matthew J McGirt; Ira M Goldstein; Kaisorn L Chaichana; Michael E Tobias; Karl F Kothbauer; George I Jallo
Journal:  Neurosurgery       Date:  2008-07       Impact factor: 4.654

9.  Spinal cord astrocytoma: pathological and treatment considerations.

Authors:  K J Minehan; E G Shaw; B W Scheithauer; D L Davis; B M Onofrio
Journal:  J Neurosurg       Date:  1995-10       Impact factor: 5.115

10.  The impact of fluorescence guidance on spinal intradural tumour surgery.

Authors:  Sven O Eicker; Frank W Floeth; Marcel Kamp; Hans-Jakob Steiger; Daniel Hänggi
Journal:  Eur Spine J       Date:  2013-01-10       Impact factor: 3.134

View more
  5 in total

1.  Molecular Biomarkers of Brain and Spinal Cord Astrocytomas.

Authors:  N A Konovalov; D S Asyutin; E G Shayhaev; S V Kaprovoy; S Yu Timonin
Journal:  Acta Naturae       Date:  2019 Apr-Jun       Impact factor: 1.845

Review 2.  Therapeutic Approaches in Adult Primary Spinal Cord Astrocytoma: A Systematic Review.

Authors:  Elena Anghileri; Morgan Broggi; Elio Mazzapicchi; Mariangela Farinotti; Andrea Botturi; Irene Tramacere; Marcello Marchetti
Journal:  Cancers (Basel)       Date:  2022-03-02       Impact factor: 6.639

Review 3.  MICROSURGICAL MANAGEMENT OF LOW-GRADE SPINAL CORD ASTROCYTOMA IN ADULTS: A PERSONAL CASE SERIES REPORT AND BRIEF LITERATURE REVIEW.

Authors:  Mirza Pojskić; Krešimir Rotim; Bruno Splavski; Kenan I Arnautović
Journal:  Acta Clin Croat       Date:  2020-09       Impact factor: 0.780

4.  Clinicopathological characteristics and survival of spinal cord astrocytomas.

Authors:  Yao-Wu Zhang; Rui-Chao Chai; Ren Cao; Wen-Ju Jiang; Wei-Hao Liu; Yu-Lun Xu; Jun Yang; Yong-Zhi Wang; Wen-Qing Jia
Journal:  Cancer Med       Date:  2020-08-10       Impact factor: 4.452

5.  Development and Validation of a Personalized Prognostic Prediction Model for Patients With Spinal Cord Astrocytoma.

Authors:  Sheng Yang; Xun Yang; Huiwen Wang; Yuelin Gu; Jingjing Feng; Xianfeng Qin; Chaobo Feng; Yufeng Li; Lijun Liu; Guoxin Fan; Xiang Liao; Shisheng He
Journal:  Front Med (Lausanne)       Date:  2022-01-18
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.